Bethanechol for Eosinophilic Esophagitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02058537
Recruitment Status : Terminated (Initial PI left, study not continued)
First Posted : February 10, 2014
Results First Posted : April 22, 2016
Last Update Posted : April 22, 2016
Information provided by (Responsible Party):
Assouline-Dayan, Yehudith, University of Iowa

Brief Summary:
The primary goals of this study are to ease the symptoms of patients with Eosinophilic Esophagitis (EoE) and to test the effectiveness of the drug bethanechol in relieving those symptoms.

Condition or disease Intervention/treatment Phase
Eosinophilic Esophagitis (EoE) Drug: Bethanechol Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 2 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Bethanechol for Treatment of Eosinophilic Esophagitis (EoE)
Study Start Date : February 2014
Actual Primary Completion Date : July 2014
Actual Study Completion Date : July 2014

Arm Intervention/treatment
Experimental: Bethanechol
Oral administration of 25 milligrams of bethanechol taken twice daily for a minimum of 7 days. Total dose taken daily for a minimum of 7 days is 50 mg.
Drug: Bethanechol
Due to the fact that this study has only 1 arm and all study subjects will receive the study drug in the same manner and dose, there are no other details to cover.

Primary Outcome Measures :
  1. Change From Baseline High Resolution Esophageal Manometry With Impedance to Day 7 [ Time Frame: Day 1 and Day 7 ]
    The high resolution esophageal manometry with impedance involves a thin, pressure-sensitive tube that is passed through the nose and into the stomach. Once in place, the tube is pulled slowly back into the esophagus (food pipe). When the tube is in the esophagus, the patient is asked to swallow several times while swallowing water, applesauce, crackers, and marshmallows. These swallows will be completed while laying down, sitting upright, and standing. The pressure of the muscle contractions will be measured along several sections of the tube. The tube is removed after the tests are completed. This test allows for a quantitative measure of the pressure in the esophagus that can be correlated to difficulty or ease of bolus swallowing.

Secondary Outcome Measures :
  1. Change From Baseline Evaluation of Esophageal Function Questionnaire to Day 7 [ Time Frame: Day 1 and Day 7 ]
    This questionnaire allows the patient to assess their own symptoms and report their opinions about drug effectiveness.

Other Outcome Measures:
  1. Change From Baseline Composite Vital Signs to Day 7 [ Time Frame: Day 1 and Day 7 ]
    Vital signs include temperature, heart rate, breathing rate, and blood pressure. This variables will be measured during the study in order to assess any negative systemic effects of the study drug. These measurements are assessed as a composite and not individually therefore are grouped together as one outcome measure.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or Female
  • Age 18-75
  • Symptoms associated with EoE such as dysphagia, heartburn, vomiting, abdominal pain, food impaction
  • Subject has signed informed consent for the administration of bethanechol that informs the patient of potential adverse events
  • Clinically or pathologically proven EoE

Exclusion Criteria:

  • Known allergy to bethanechol
  • Asthma
  • Pregnant or breast-feeding women
  • Severe neurological problems
  • Severe diabetes
  • Achalasia
  • Known allergy to lidocaine or other local anesthetic
  • Hypothyroidism
  • Peptic ulcer
  • Pronounced bradycardia or hypotension
  • Vasomotor instability
  • Coronary artery disease
  • Epilepsy
  • Parkinsonism
  • Weakened gastrointestinal or bladder wall
  • Mechanical obstruction of the gastrointestinal tract or bladder neck
  • Urinary bladder surgery in the 6 months prior to the study
  • Gastrointestinal resection and anastomosis
  • Spastic gastrointestinal disturbances
  • Acute inflammatory lesions of the gastrointestinal tract
  • Peritonitis
  • Marked vagotonia

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02058537

United States, Iowa
University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States, 52242
Sponsors and Collaborators
University of Iowa
Principal Investigator: Yehudith Assouline-Dayan, MD University of Iowa

Responsible Party: Assouline-Dayan, Yehudith, Clinical Assistant Professor, University of Iowa Identifier: NCT02058537     History of Changes
Other Study ID Numbers: Bethanechol
First Posted: February 10, 2014    Key Record Dates
Results First Posted: April 22, 2016
Last Update Posted: April 22, 2016
Last Verified: March 2016

Additional relevant MeSH terms:
Eosinophilic Esophagitis
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Leukocyte Disorders
Hematologic Diseases
Hypersensitivity, Immediate
Immune System Diseases
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Muscarinic Agonists
Cholinergic Agonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action